Treating the patient with differentiated thyroid cancer with thyroglobulin-positive iodine-131 diagnostic scan-negative metastases: Including comments on the role of serum thyroglobulin monitoring in tumor surveillance
References (66)
- et al.
Thyroid cancer diagnosis and management
Clin Lab Med
(1993) - et al.
Papillary thyroid carcinoma: a 10 year follow-up report of the impact of therapy in 576 patients
Am J Med
(1981) - et al.
The changing role of radioiodine in the management of differentiated thyroid cancer
Semin Nucl Med
(1997) - et al.
Thyroglobulin measurement. Techniques, clinical benefits, and pitfalls. Endocrinol Metab
Clin North Am
(1995) - et al.
Thyroglobulin measurement and postablative iodine-131 total body scan after total thyroidectomy for differentiated thyroid carcinoma in patients with no evidence of disease
Eur J Cancer
(1996) - et al.
Thyroid cancer nodal metastases: biologic significance and therapeutic considerations
Surg Oncol Clin N Am
(1996) - et al.
Surveillance after treatment for well differentiated thyroid cancer: audit for chest radiography
Clin Oncol (R Coll Radiol)
(1994) Papillary thyroid carcinoma
Endocrinol Metab Clin North Am
(1990)- et al.
Thyroid cancer diagnosis and management
Clin Lab Med
(1993) - et al.
Imaging modalities in the follow-up of non-iodine avid thyroid carcinoma
Am J Otolaryngol
(1994)
Papillary and follicular thyroid carcinoma
N Engl J Med
Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989
Surgery
Follicular cell-derived thyroid carcinomas
Cancer Treat Res
Control of thyroglobulin synthesis and secretion
N Engl J Med
AACE clinical practice guidelines for the management of thyroid carcinoma
Endocrine Practice
Papillary thyroid carcinoma: the impact of therapy in 576 patients
Medicine
Thyroid remnant 131I ablation for papillary and follicular thyroid carcinoma
Thyroid
Differentiated thyroid cancer: long-term impact of initial therapy
Trans Am Clin Climatol Assoc
The effects of radioactive iodine in thyroid remnant ablation and treatment of well differentiated thyroid carcinoma
Br J Radiol
131I therapy for elevated thyroglobulin levels
Thyroid
Low levels of serum thyroglobulin after withdrawal of thyroid suppression therapy in the follow up of differentiated thyroid carcinoma
Eur J Nucl Med
Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels
J Nucl Med
Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan
J Clin Endocrinol Metab
Radioimmunoassay for measurement of thyroglobulin in human serum
J Clin Invest
Assessment of the influence of thyroglobulin (Tg) autoantibodies and other interfering factors on the use of serum Tg as tumor marker in differentiated thyroid carcinoma
Thyroid
Nonisotopic “sandwich” immunoassay of thyroglobulin in serum by the biotinstreptavidin technique: evaluation and comparison with an immunoradiometric assay
Clin Chem
A new immunoradiometric assay (IRMA) system for thyroglobulin measurement in the follow-up of thyroid cancer patients
Eur J Nucl Med
Human thyroglobulin reference material (CRM 457). 1st Part: Assessment of homogeneity, stability and immunoreactivity
Ann Biol Clin (Paris)
Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma
J Clin Endocrinol Metab
Serum thyroglobulin determination in the follow-up of patients with differentiated thyroid carcinoma
Eur J Endocrinol
Is serum thyroglobulin a useful marker for thyroid cancer in patients who have not had ablation of residual thyroid tissue?
Thyroid
The use of radioactive iodine in patients with papillary and follicular thyroid cancer
J Clin Endocrinol Metab
Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer
J Clin Endocrinol Metab
Cited by (62)
Low correlation between serum thyroglobulin and <sup>131</sup>I radioiodine whole body scintigraphy: implication for postoperative disease surveillance in differentiated thyroid cancer
2022, Clinical ImagingCitation Excerpt :Patient selection for postoperative RAI ablation therapy is based on clinical and histopathologic risk stratification. Empiric RAI treatment of Tg positive, PA-WBS negative patients remains controversial.21–23 Proponents of this approach contend that small tumor size or micrometastasis maybe below the detection sensitivity of diagnostic RAI whole-body scintigraphy.
Simultaneous measurements of single gamma ray of <sup>131</sup>I and annihilation radiation of <sup>18</sup>F with Compton PET hybrid camera
2021, Applied Radiation and IsotopesCitation Excerpt :On the contrary, when no accumulation is observed in the anterior neck, 131I scintigraphy alone is insufficient to determine whether treatment should be continued. This can be attributed to the refractoriness to internal 131I therapy (Fatourechi and Hay, 2000) (Frilling et al., 2000). Although 131I is more likely to accumulate in normal thyroid tissues and well-differentiated thyroid cancer tissues, it is less likely to accumulate in poorly differentiated to undifferentiated thyroid cancer tissues.
Postoperative Management of Thyroid Carcinoma
2008, Surgical Oncology Clinics of North AmericaCitation Excerpt :In patients who have non–iodine-avid DTC recurrence demonstrated by elevated Tg alone and a negative WBS, some authors advocate empiric 131I therapy on the theory that micrometastases too small to be detected by low-dose WBS may still take up some iodine (such lesions are sometimes seen on posttherapy scans) [46,47]. This strategy is controversial, however, and its efficacy has been questioned [48–50]. The most common sites of distant metastases from DTC are the lungs, bone, and central nervous system.